Skip to main content
OpenTrials
Completed

NCT Number: NCT02508844

Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn

The purpose of the study is to investigate if the probiotics Vivomixx® can affect gestational weight gain, microbiota and pregnancy complications in pregnant obese women and birth weight body composition of their infants.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Accumulating evidence indicates that the gut microbiota plays a significant role in obesity and because the "ideal" composition of the gut microbiota remains poorly understood, modulation of the gut microbiota composition represents a potentially attractive treatment option against excessive gestational weight gain and adverse outcomes for obese pregnant women and their newborn. Dietary supplements in the form of probiotics could be an efficient treatment for controlling weight gain in pregnancy by inducing changes in the gut microbiota and could have influence on infant's microbiota, which could have important implications for infant development and health.

A pilot study including 50 obese pregnant nulliparous with BMI between 30-35 kg/m2 will, after accepting participation, be randomized to receive daily placebo or probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery. The infants will be followed until 9 months of age. Shortly after birth, tissue composition will be measured in the infants by DEXA-scanning. The women will be monitored by weight, blood-, fecal- and urine samples, diet questionnaires and hospital record review. Vivomixx® is a probiotic mixture of 8 probiotic strains, (Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus and Streptococcus thermophilus).

This is the first pilot study in which the probiotic Vivomixx® are added in a randomized fashion to the standard of care in obese pregnant women. 50 pregnant women are planned to be included. The aim of this group size is to clarify the feasibility, compliance and to estimate parameters such as the standard deviation which will be used in a sample size calculation for a full-scale trial.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • BMI ≥ 30 and ≤35 kg/m2- calculated from pre-pregnancy weight
  • Primiparous singleton pregnancy
  • Able to read and speak Danish
  • Normal ultrasound scan of the fetus at gestational age 12-14
  • Oral glucose tolerance test at gestational age 14-20

Exclusion criteria

  • Pregnancy at > 20 weeks gestation at recruitment
  • Pre-gestational diabetes or other serious diseases
  • Multiple pregnancy
  • Previous bariatric surgery
  • Ingestion of probiotics < 1 month before the inclusion or ingestion of other kinds of probiotics than the study probiotics

Treatment and study plan

Vivomixx®

Dietary Supplement

probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery

Placebo

Dietary Supplement

Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.

Primary outcomes

  1. Gestational weight gain

    Time frame: week 36-37 of pregnancy

    weight at gestational age 36-37-weeks minus self-reported pre-pregnancy weight

  2. Change in glucose levels (Oral glucose tolerance test)

    Time frame: baseline (week 14-20) and 27-30 of pregnancy

Secondary outcomes

  1. Change in fecal microbiota

    Time frame: baseline (week 14-20) and week 36-37 of pregnancy

  2. Amount of fat tissue in the newborn infant

    Time frame: at birth

    examined by a DEXA-scanning

  3. Change in HbA1c

    Time frame: baseline (week 14-20) and week 36-37 of pregnancy

Sponsors and collaborators

Lead sponsor

Hvidovre University Hospital

Other

Collaborators

  • Statens Serum Institut
  • University of Copenhagen

Registry information

Official study title

The POP-study: Effect of Probiotics on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn - a Randomized, Double-blind Placebo Controlled Trial With Vivomixx®

Acronym: POP

Important dates

Study start
2015
Primary completion
2018
Study completion
2020
First posted
Jul 27, 2015
Registry last updated
Mar 23, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.